巢蛋白、微管相关蛋白与精神分裂症相关性研究

Nestin and MAP-2 with schizophrenia correlation studies

目的探讨巢蛋白、微管相关蛋白与精神分裂症相关性。方法选择2018年3月~2019年3月我院收治的60例首发精神分裂症患者为病例组,同期于社区体检的健康自愿者随机60例为对照组。所有人员均行巢蛋白、微管相关蛋白检测,比较两组的检测结果。结果病例组巢蛋白和微管相关蛋白水平明显低于对照组,P<0.01;患者经6周治疗后,精神分裂症阳性与阴性症状量表(PANSS)评分较治疗前明显下降,P<0.01。治疗后巢蛋白、微管相关蛋白水平存在一定的升高,但对比治疗前,差异不显著,P>0.05。经Pearson相关性分析提示,巢蛋白、微管相关蛋白水平与精神分裂症的症状程度呈负相关。结论巢蛋白、微管相关蛋白可作为精神分裂症早期干预的一项重要生化指标。

Objective To investigate relationship of Nestin and MAP-2 correlation with schizophrenia. Methods 60 patients with first episode schizophrenia admitted to our hospital from March 2018 to September 2019 were selected as the case group,and 60 healthy volunteers who underwent community physical examination during the same period were randomly selected as the control group.. All personnel were tested Nestin and MAP-2 in the plasma. comparison of two groups of test results. Results The levels of Nestin and MAP-2 in the case group were significantly lower than those in the control group(P<0.01). After 6 weeks of treatment,the PANSS score of patients with schizophrenia was significantly lower than that before treatment(P<0.01). Nestin and MAP-2 levels after treatment there is a rise,but compared to before the treatment,no significant difference(P>0.05). The Pearson correlation analysis suggests that Nestin and MAP-2 levels and negatively correlated with the degree of symptoms of schizophrenia. Conclusion Nestin and MAP-2 can be used for schizophrenia is an important biochemical indicator of early intervention.